Ali Shilatifard

Ali Shilatifard

Auto-generated profile, based on publicly available information

Ali Shilatifard

Simpson Querrey Center for Epigenetics, Northwestern University Feinberg School of Medicine

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
RGRogan A. Grant
Rogan A. Grant
LMLuisa Morales-Nebreda
Luisa Morales-Nebreda
NMNikolay S. Markov
Nikolay S. Markov
SSSuchitra Swaminathan
Suchitra Swaminathan
MQMelissa Querrey
Melissa Querrey
RWRichard G. Wunderink
Richard G. Wunderink

3 June 2016 in Science
Verified
Journal Article
Closed access
PDF file
APAndrea Piunti
Andrea Piunti
ASAli Shilatifard
Ali Shilatifard
A balancing act in modifying chromatin: Chromatin modifiers add chemical groups to histones, the proteins that package DNA. These modifications are central to cellular development, and mutations in their molecular machinery are linked to a variety of human diseases. Piunti and Shilatifard review the balance between the prototypic chromatin modifiers Polycomb and COMPASS complexes and their role in gene regulation and normal development. Although originally identified as indispensible regulators of fruit fly development, related roles have been identified in other organisms. Furthermore, mutations in human homologs have been implicated in various cancers. As such, these complexes may serve as effective targets for epigenetic therapies. Science , this issue p. 10.1126/science.aad9780

20 November 2019 in Genome Biology
Verified
Journal Article
Open access
PDF file
ZZZibo Zhao
Zibo Zhao
ASAli Shilatifard
Ali Shilatifard
The epigenetic modifications of histones are versatile marks that are intimately connected to development and disease pathogenesis including human cancers. In this review, we will discuss the many different types of histone modifications and the biological processes with which they are involved. Specifically, we review the enzymatic machineries and modifications that are involved in cancer development and progression, and how to apply currently available small molecule inhibitors for histone modifiers as tool compounds to study the functional significance of histone modifications and their clinical implications.

8 May 2018 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
FCFei Xavier Chen
Fei Xavier Chen
ESEdwin R. Smith
Edwin R. Smith
ASAli Shilatifard
Ali Shilatifard

27 February 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
APAndrea Piunti
Andrea Piunti
RHRintaro Hashizume
Rintaro Hashizume
MMMarc A Morgan
Marc A Morgan
EBElizabeth T Bartom
Elizabeth T Bartom
CHCraig M Horbinski
Craig M Horbinski
ASAli Shilatifard
Ali Shilatifard
Nucleosomes containing mutant K27M histones in diffuse intrinsic pediatric gliomas (DIPG) exclude PRC2 binding and recruit BET bromodomain proteins; however, residual PRC2-dependent repression of specific loci, is required for DIPG oncogenesis. These results provide a rationale for targeting these epigenetic regulators in patients. Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor characterized by rapid and uniform patient demise1. A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors and results in a lysine-to-methionine substitution (H3K27M)2,3. Expression of this histone mutant is accompanied by a reduction in the levels of polycomb repressive complex 2 (PRC2)-mediated H3K27 trimethylation (H3K27me3), and this is hypothesized to be a driving event of DIPG oncogenesis4,5. Despite a major loss of H3K27me3, PRC2 activity is still detected in DIPG cells positive for H3K27M6,7. To investigate the functional roles of H3K27M and PRC2 in DIPG pathogenesis, we profiled the epigenome of H3K27M-mutant DIPG cells and found that H3K27M associates with increased H3K27 acetylation (H3K27ac). In accordance with previous biochemical data5, the majority of the heterotypic H3K27M-K27ac nucleosomes colocalize with bromodomain proteins at the loci of actively transcribed genes, whereas PRC2 is excluded from these regions; this suggests that H3K27M does not sequester PRC2 on chromatin. Residual PRC2 activity is required to maintain DIPG proliferative potential, by repressing neuronal differentiation and function. Finally, to examine the therapeutic potential of blocking the recruitment of bromodomain proteins by heterotypic H3K27M-K27ac nucleosomes in DIPG cells, we performed treatments in vivo with BET bromodomain inhibitors and demonstrate that they efficiently inhibit tumor progression, thus identifying this class of compounds as potential therapeutics in DIPG.

15 March 2021 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
APAndrea Piunti
Andrea Piunti
ASAli Shilatifard
Ali Shilatifard